Publication date: Apr 30, 2019
CARLSBAD, Calif. , April 29, 2019 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQX: ISCO) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the completion of subject enrollment in its phase 1 clinical trial of ISC-hpNSC(R) for the treatment of Parkinson’s disease.
The fourth subject of the third cohort, who was the twelfth and final subject of the phase 1 clinical study, was successfully transplanted with the highest dose of ISC-hpNSC(R) cells.
“We are excited to announce the completion of enrollment of the world’s first approved human pluripotent stem cell-based clinical trial for the treatment of Parkinson’s disease.
The goal of this study is to assess the safety and incidence of treatment-emergent adverse events after intracerebral transplantation of 30 million, 50 million, and 70 million ISC-hpNSC(R) cells into the substantia nigra and striatum of patients with Parkinson’s disease.
About ISC-hpNSC(R) International Stem Cell Corporation’s proprietary ISC-hpNSC(R) consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells.
Preclinical studies in rodents and non-human primates have shown improvement in Parkinson’s disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC(R).
International Stem Cell Corporation believes that ISC-hpNSC(R) may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.
About International Stem Cell Corporation International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products.
To subscribe to receive ongoing corporate communications, please click on the following link: To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: and Safe harbor statement Statements pertaining to anticipated developments, clinical studies expectations (including timing), resource availability, progress of research and development, and other opportunities for the Company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.